Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
5 Results for "
seizure severity
" in MedChemExpress (MCE) Product Catalog:
Products (5)
5 Results for "seizure severity" in MCE Product Catalog:
Target:
Research Areas:
JW-65 is a selective TRPC3 channel inhibitor with favorable blood-brain barrier penetration. JW-65 directly binds to human TRPC3 protein and modulates calcium signaling to reduce seizure susceptibility. JW-65 reduces seizure incidence, severity, and duration while prolonging seizure latency in multiple seizure models. JW-65 alleviates Aβ‑induced neuronal damage. JW-65 serves as a valuable tool for research on epilepsy, seizure disorders, and Alzheimer’s disease .
Cat. No.: HY-W101673
CAS No.: 2416-95-7
Target:
Research Areas:
Dipropofol is a dimeric derivative of Propofol (HY-B0649) with antioxidant and antibacterial activities. Dipropofol terminates free radical chain reactions, scavenges DPPH free radicals and inhibits lipid peroxidation. Dipropofol protects cells from death induced by glutamate, Aβ(25-35) and buthionine sulfoximine, and increases the survival rate of mice exposed to oxygen. Dipropofol selectively activates tonic GABAA currents, hyperpolarizes resting membrane potential, reduces action potential firing, and alleviates the severity of seizures induced by Kainic acid. Dipropofol can be used in the research of Gram-positive bacterial infections, Alzheimer's disease, cerebral ischemia-related neuronal injury, oxygen toxicity and temporal lobe epilepsy .
Target:
Research Areas:
DP-b99 is a blood-brain barrier-permeable inhibitor of CYP2C9 and MMP-9, with a Ki value of 4.655 μM against CYP2C9. DP-b99 inhibits CYP2C9 via apparent non-competitive inhibition, mainly chelates pathological Zn 2+ in the membrane environment, attenuates the elevation of intracellular Zn 2+ and Ca 2+ levels, delays seizure onset and reduces seizure severity, and also prevents MMP-9-dependent dendritic spine remodeling, β-dystroglycan cleavage and gelatinase activity. DP-b99 can be used in the research of acute ischemic stroke, epileptogenesis and stroke .
Cat. No.: HY-120146
CAS No.: 184845-43-0
Target:
Research Areas:
NNC 05-2090 is aGABA uptake inhibitor and inhibitor of the β-GABA transporter (BGT-1) (IC50 sub>: 10.6 μM). NNC 05-2090 also inhibits mGAT2 with a Ki value of 1.4 μM. NNC 05-2090 has anticonvulsant activity and can be used in the study of epilepsy and neurological diseases .
Cat. No.: HY-W101673R
CAS No.: 2416-95-7
Research Areas:
Dipropofol (Standard) is the analytical standard of Dipropofol. This product is intended for research and analytical applications. Dipropofol is a dimeric derivative of Propofol (HY-B0649) with antioxidant and antibacterial activities. Dipropofol terminates free radical chain reactions, scavenges DPPH free radicals and inhibits lipid peroxidation. Dipropofol protects cells from death induced by glutamate, Aβ(25-35) and buthionine sulfoximine, and increases the survival rate of mice exposed to oxygen. Dipropofol selectively activates tonic GABAA currents, hyperpolarizes resting membrane potential, reduces action potential firing, and alleviates the severity of seizures induced by Kainic acid. Dipropofol can be used in the research of Gram-positive bacterial infections, Alzheimer's disease, cerebral ischemia-related neuronal injury, oxygen toxicity and temporal lobe epilepsy .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
